Article

Phakic IOL delivers for patients with moderate, high myopia

Author(s):

San Diego-The Artisan Phakic IOL (Ophtec BV, Groningen, The Netherlands) provides overall high satisfaction for patients with moderate to high myopia. Night vision problems from higher-order aberrations, decentration of the lens, and pupil size versus the optic disparity of the IOL should be investigated further, according to Randy Nuijts, MD.

In a study of this lens, 66 patients (mean age, 44 years) took part; 61 patients underwent bilateral implantation and five unilateral. Mean follow- up was 18 months.

The investigators used a validated questionnaire that consisted of 66 items that the patients completed. From the 66 items, seven scales were constructed that measured the patients' quality of vision, global satisfaction, quality of corrected and uncorrected vision, quality of night vision, glare, and daytime and nighttime driving vision, Dr. Nuijts explained at the American Society of Cataract and Refractive Surgery annual meeting.

Night vision had an overall score of 3.2 on a scale of 0 to 5; 44% of patients reported that their night vision was very poor and 73% reported that it was better or the same as that before the surgery, and 27% indicated that it was worse than before the surgery.

The overall glare score was 2.9 on a scale of 0 to 5; 44% of the patients reported that they had more glare from light at night compared with before the surgery, 7% reported glare from oncoming headlights, and 58% stated that the glare was more bother-some than before the sur-gery. Starbursts and halos increased after implantation of the IOL.

The investigators then analyzed the correlation between the clinical parameters of satisfaction and the scales.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.